Drugs in Dev.
Trauma (Emergency, Injury, Surgery)
IND Enabling
Canada 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revive Therapeutics Advances with Next-Generation Bucillamine Development
Details : Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
June 04, 2025
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Attwill Medical Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the clinical and commercial development of Revive’s lyophilized formulation of Bucillamine, a potent antioxidant and anti-inflammatory and may be helpful for orphan indications in rare inflammatory disorders such as ischemia-...
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Attwill Medical Solutions
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ODD validates strategy in pursuing novel uses of Bucillamine, a cysteine derivative reactivating this endogenous defense against oxidant injury for rare disorders and life-threatening conditions, including infectious diseases and preventing IRI.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revive believes the use of Bucillamine during liver transplantation has the potential to be a safe and effective approach to address the unmet medical need for a novel strategy to limit or prevent ischemia–reperfusion injury (IRI) during liver transpla...
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : Bucillamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Chitosan-PRP
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ortho Regenerative Technologies Receives Clinical Hold Letter from The U.S. FDA
Details : FDA has requested additional CMC related information on Ortho Regenerative's Investigational New Drug application to begin a phase I/II clinical trial for ORTHO-R, its drug/biologic combination product candidate used as an adjunct to SOC surgery in rota...
Product Name : ORTHO-R
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 04, 2021
Lead Product(s) : Chitosan-PRP
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
